Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724993 | 0.88 | HTT (0.63) | ALDH1A1LMNAHTTKMT2AMEN1 | |
| SCHEMBL11748653 | 0.83 | KMT2A (0.67) | ALDH1A1LMNAL3MBTL1HTTKMT2A | |
| SCHEMBL10814631 | 0.79 | HTT (0.60) | ALDH1A1LMNAHTTKMT2AMEN1 | |
| SCHEMBL10643441 | 0.79 | ALDH1A1 (0.57) | ALDH1A1LMNAL3MBTL1HTTKMT2A | |
| SCHEMBL6163049 | 0.78 | PDPK1 (0.59) | ALDH1A1HTTKMT2AMEN1EPHX1 | |
| SCHEMBL4512600 | 0.76 | ALDH1A1 (0.60) | ALDH1A1LMNAHTTKMT2AMEN1 | |
| SCHEMBL16692424 | 0.76 | HTT (0.50) | ALDH1A1LMNAHTTKMT2AMEN1 | |
| SCHEMBL2265338 | 0.75 | ALDH1A1 (0.69) | ALDH1A1LMNAL3MBTL1HTTHPGD | |
| SCHEMBL10777155 | 0.75 | ALDH1A1 (0.54) | ALDH1A1LMNAL3MBTL1HTTKMT2A | |
| SCHEMBL16681711 | 0.75 | HTT (0.49) | ALDH1A1LMNAHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-4661520-A | Cyanoguanidine useful as an animal growth promoting agent | THE DOW CHEMICAL COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| US-4661520-A | Cyanoguanidine useful as an animal growth promoting agent | THE DOW CHEMICAL COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | ALDH1A1 732/4885LMNA 1812/4885L3MBTL1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.